Published in Nat Rev Cancer on February 01, 2003
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A (2004) 2.25
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A (2003) 2.23
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology (2012) 2.23
Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res (2006) 1.75
Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A (2009) 1.59
New developments in the medical management of prostate cancer. Mayo Clin Proc (2010) 1.41
Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2013) 1.40
Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest (2010) 1.39
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer (2006) 1.37
Endothelin receptors and pain. J Pain (2009) 1.27
Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol (2011) 1.21
Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem Biol (2012) 1.17
Pulmonary artery adventitial fibroblasts cooperate with vasa vasorum endothelial cells to regulate vasa vasorum neovascularization: a process mediated by hypoxia and endothelin-1. Am J Pathol (2006) 1.16
Human mesenchymal stem cell-replicative senescence and oxidative stress are closely linked to aneuploidy. Cell Death Dis (2013) 1.16
Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res (2011) 1.16
Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer. Diagn Pathol (2013) 1.11
Endothelin receptors as novel targets in tumor therapy. J Transl Med (2004) 1.07
Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res (2009) 1.05
Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer. Breast Cancer Res (2009) 1.05
Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J (2011) 1.05
Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett (2009) 1.04
Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J (2011) 1.04
Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells. Cancer Biol Ther (2012) 1.04
Transcriptional profiling in an MPNST-derived cell line and normal human Schwann cells. Neuron Glia Biol (2004) 1.02
Mechanism of cancer pain. Mol Interv (2010) 1.00
Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia (2005) 0.98
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer (2005) 0.98
Perinecrotic hypoxia contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Am J Pathol (2007) 0.98
Feeling too hot or cold after breast cancer: is it just a nuisance or a potentially important prognostic factor? Int J Hyperthermia (2010) 0.97
Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res (2011) 0.97
The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev Urol (2006) 0.96
Endothelin receptors: what's new and what do we need to know? Am J Physiol Regul Integr Comp Physiol (2009) 0.95
Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin-induced apoptosis. Clin Orthop Relat Res (2011) 0.94
Early progress in epigenetic regulation of endothelin pathway genes. Br J Pharmacol (2013) 0.93
Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. Haematologica (2011) 0.93
Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev (2014) 0.92
Effectiveness of bone metastases treatment by sm-153 oxabifore in combination with monoclonal antibody denosumab (xgeva): first experience. World J Nucl Med (2013) 0.92
Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol (2012) 0.92
Imaging angiogenesis of genitourinary tumors. Nat Rev Urol (2010) 0.90
Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate (2013) 0.89
Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol (2015) 0.89
Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol (2014) 0.89
Endothelin receptor antagonists. World J Urol (2005) 0.89
Endothelin (ET)-1 and ET-3 promote expression of c-fos and c-jun in human choriocarcinoma via ET(B) receptor-mediated G(i)- and G(q)-pathways and MAP kinase activation. Br J Pharmacol (2008) 0.89
Expression of endothelin 2 and localized clear cell renal cell carcinoma. Hum Pathol (2011) 0.89
Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am J Pathol (2003) 0.88
Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma. Transl Oncol (2014) 0.87
Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis. Clin Exp Metastasis (2006) 0.87
Endothelins and their receptors in cancer: identification of therapeutic targets. Pharmacol Res (2011) 0.85
EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma. Oncotarget (2014) 0.85
Identification of a novel role for endothelins within the oviduct. Endocrinology (2010) 0.85
Expression of endothelin-A-receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer (2004) 0.85
Hematopoietic colony-stimulating factors: new players in tumor-nerve interactions. J Mol Med (Berl) (2010) 0.84
TWIST interacts with endothelin-1/endothelin A receptor signaling in osteosarcoma cell survival against cisplatin. Oncol Lett (2013) 0.84
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs (2009) 0.83
Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol (2008) 0.83
Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer (2005) 0.83
Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma. Br J Cancer (2012) 0.83
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst (2014) 0.83
Astrocyte elevated gene-1 regulates osteosarcoma cell invasion and chemoresistance via endothelin-1/endothelin A receptor signaling. Oncol Lett (2012) 0.81
ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs (2008) 0.81
A candidate gene approach for virally induced cancer with application to HIV-related Kaposi's sarcoma. Int J Cancer (2013) 0.81
Antioxidant treatment promotes prostate epithelial proliferation in Nkx3.1 mutant mice. PLoS One (2012) 0.80
Expression of endothelin-1 and its receptors in Cisplatin-induced acute renal failure in mice. Korean J Physiol Pharmacol (2008) 0.80
Feeling cold and other underestimated symptoms in breast cancer: anecdotes or individual profiles for advanced patient stratification? EPMA J (2017) 0.80
The endothelin-integrin axis is involved in macrophage-induced breast cancer cell chemotactic interactions with endothelial cells. J Biol Chem (2014) 0.79
Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Rev Urol (2007) 0.79
Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer. Asian J Androl (2014) 0.79
Stromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasis. Mol Cancer Ther (2009) 0.79
Calcium channels activated by endothelin-1 in human trophoblast. J Physiol (2004) 0.79
Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells. PLoS One (2014) 0.79
Endothelin B receptor expression correlates with tumour angiogenesis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer (2013) 0.79
Activation of the endothelin system mediates pathological angiogenesis during ischemic retinopathy. Am J Pathol (2014) 0.78
Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor. BMC Cancer (2008) 0.78
Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease. Am J Physiol Gastrointest Liver Physiol (2009) 0.78
Dangerous liaisons: molecular basis for a syndemic relationship between Kaposi's sarcoma and P. falciparum malaria. Front Microbiol (2013) 0.78
Differential endothelin receptor expression and function in rat myometrial cells and leiomyoma ELT3 cells. Endocrinology (2009) 0.78
Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. J Clin Pathol (2006) 0.78
Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model. Cancer Biol Ther (2009) 0.78
The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification. Br J Cancer (2005) 0.78
Endothelin-Mediated Changes in Gene Expression in Isolated Purified Rat Retinal Ganglion Cells. Invest Ophthalmol Vis Sci (2015) 0.78
Epithelial cells captured from ductal carcinoma in situ reveal a gene expression signature associated with progression to invasive breast cancer. Oncotarget (2016) 0.78
The role of osteoclasts in breast cancer bone metastasis. J Bone Oncol (2016) 0.78
Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model. J Cancer Res Clin Oncol (2009) 0.77
Synthesis and in vivo evaluation of an (18)F-labeled glycoconjugate of PD156707 for imaging ETA receptor expression in thyroid carcinoma by positron emission tomography. Am J Nucl Med Mol Imaging (2013) 0.77
Identification of molecular targets in urologic oncology. World J Urol (2008) 0.77
Expression of endothelin 1 and its angiogenic role in meningiomas. Virchows Arch (2006) 0.77
Epigenetic suppression of neprilysin regulates breast cancer invasion. Oncogenesis (2016) 0.76
Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions. EPMA J (2014) 0.76
Early survival factor deprivation in the olfactory epithelium enhances activity-driven survival. Front Cell Neurosci (2013) 0.76
Control of the adaptive immune response by tumor vasculature. Front Oncol (2014) 0.76
Divergence in endothelin-1- and bradykinin-activated store-operated calcium entry in afferent sensory neurons. ASN Neuro (2015) 0.76
Inhibitory effect of endothelin A receptor blockade on tumor growth and liver metastasis of a human gastric cancer cell line. Gastric Cancer (2007) 0.76
Bone Targeted Therapies for Bone Metastasis in Breast Cancer. J Clin Med (2013) 0.76
Exploiting drug repositioning and the brain microenvironment to treat brain metastases. Neuro Oncol (2016) 0.75
The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol (2004) 0.75
Serum big endothelin-1 as a biomarker in oral squamous cell carcinoma patients: an analytical study. J Appl Oral Sci (2015) 0.75
Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res (2005) 1.69
Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A (2009) 1.59
Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem (2002) 1.56
Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res (2011) 1.53
Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2013) 1.40
Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol (2002) 1.34
Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res (2009) 1.19
Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol Cancer Ther (2006) 1.08
Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J Biol Chem (2003) 1.05
Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res (2003) 1.03
Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Res (2007) 1.03
Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem (2004) 1.00
Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clin Cancer Res (2004) 0.99
Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res (2007) 0.98
Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells. PLoS One (2010) 0.98
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther (2007) 0.96
Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. J Mol Med (Berl) (2012) 0.93
Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol (2007) 0.92
The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer. Am J Physiol Regul Integr Comp Physiol (2010) 0.92
LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J Mol Med (Berl) (2012) 0.90
Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. Nucleic Acids Res (2013) 0.90
Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells. Life Sci (2012) 0.89
The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis (2014) 0.88
Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther (2006) 0.88
Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Exp Biol Med (Maywood) (2006) 0.88
β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. J Am Soc Nephrol (2013) 0.88
Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am J Pathol (2003) 0.88
Effects of a selective bradykinin B1 receptor antagonist on increased plasma extravasation in streptozotocin-induced diabetic rats: distinct vasculopathic profile of major key organs. Eur J Pharmacol (2005) 0.87
Early endothelial dysfunction in cholesterol-fed rabbits: a non-invasive in vivo ultrasound study. Cardiovasc Ultrasound (2004) 0.86
Long-term effects of ovariectomy and estrogen replacement treatment on endothelial function in mature rats. Maturitas (2003) 0.86
The kinin system mediates hyperalgesia through the inducible bradykinin B1 receptor subtype: evidence in various experimental animal models of type 1 and type 2 diabetic neuropathy. Biol Chem (2006) 0.86
Classification of endothelin receptors and antagonists in clinical development. Clin Sci (Lond) (2002) 0.86
Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci (Lond) (2002) 0.85
Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: blockade with a selective bradykinin B1 receptor antagonist. Regul Pept (2005) 0.83
Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer. Can J Physiol Pharmacol (2010) 0.82
ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood) (2006) 0.81
Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells. Can J Physiol Pharmacol (2010) 0.81
Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Can J Physiol Pharmacol (2002) 0.81
Endothelin-B receptor blockade inhibits molecular effectors of melanoma cell progression. J Cardiovasc Pharmacol (2004) 0.81
Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clin Sci (Lond) (2002) 0.80
Endothelins regulate mediator production of rat tissue-cultured mucosal mast cells. Up-regulation of Th1 and inhibition of Th2 cytokines. J Leukoc Biol (2002) 0.80
Inhibition of type 1 diabetic hyperalgesia in streptozotocin-induced Wistar versus spontaneous gene-prone BB/Worchester rats: efficacy of a selective bradykinin B1 receptor antagonist. J Neuropathol Exp Neurol (2005) 0.80
Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. Exp Biol Med (Maywood) (2006) 0.79
Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats. Am J Hypertens (2005) 0.79
The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis. Life Sci (2012) 0.79
Modulating effect of a selective endothelin A receptor antagonist on pulmonary endothelin system protein expression in experimental diaphragmatic hernia. J Pediatr Surg (2005) 0.78
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. Mol Cancer Ther (2014) 0.78
Convergent pathways link the endothelin A receptor to the beta-catenin: the beta-arrestin connection. Cell Cycle (2009) 0.78
Plasma levels of endothelin-1, big endothelin-1 and thromboxane following acute pulmonary air embolism. Respir Physiol Neurobiol (2003) 0.77
Profile of endothelin isopeptides and markers of oxidative stress alongside the onset of streptozotocin-type I diabetes in rats. J Cardiovasc Pharmacol (2004) 0.77
Beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase. Can J Physiol Pharmacol (2010) 0.77
Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor. J Cardiovasc Pharmacol (2004) 0.77
Targeting endothelin receptor type A in human cervical carcinoma cells. J Cardiovasc Pharmacol (2004) 0.77
Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan. J Cardiovasc Pharmacol (2004) 0.76
Effects of a selective endothelin A receptor antagonist, ABT-627, in healthy normotensive anaesthetized rats developing acute pulmonary air embolism. Clin Sci (Lond) (2002) 0.75
Inhibition of endothelin-converting enzyme for protection against neointimal proliferation following balloon angioplasty of the rat carotid artery. Can J Physiol Pharmacol (2002) 0.75
Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond) (2002) 0.75
Proinflammatory cytokines are not released in the circulation following acute pulmonary thromboembolism in pigs. J Invest Surg (2002) 0.75
Integrated in vivo pharmacology using an instrumented, unrestrained and conscious rat platform: application to rat models of diabetes. J Pharmacol Toxicol Methods (2005) 0.75
Endothelin receptor blockade inhibits the growth of human papillomavirus-associated cervical carcinoma. Clin Sci (Lond) (2002) 0.75
Triple vasopeptidase inhibition of angiotensin-converting enzyme/neutral endopeptidase/endothelin-converting enzyme activities on the hemodynamic profile of chronically instrumented unrestrained conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol (2004) 0.75
ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clin Sci (Lond) (2002) 0.75
Inhibition of basal and stimulated release of endothelin-1 from guinea pig tracheal epithelial cells in culture by beta 2-adrenoceptor agonists and cyclic AMP enhancers. Inflammation (2007) 0.75